PDT Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.7M | Buy |
156,693
+51,772
| +49% | +$1.88M | 0.32% | 81 |
|
|
2025
Q1 | $3.8M | Buy |
104,921
+56,062
| +115% | +$2.03M | 0.27% | 118 |
|
|
2024
Q4 | $2.06M | Sell |
48,859
-17,334
| -26% | -$729K | 0.18% | 197 |
|
|
2024
Q3 | $3.68M | Buy |
66,193
+13,718
| +26% | +$762K | 0.33% | 71 |
|
|
2024
Q2 | $2.16M | Buy |
52,475
+1
| +0% | +$41 | 0.2% | 186 |
|
|
2024
Q1 | $2.45M | Buy |
52,474
+4,973
| +10% | +$232K | 0.23% | 153 |
|
|
2023
Q4 | $2.27M | Buy |
47,501
+14,272
| +43% | +$682K | 0.25% | 125 |
|
|
2023
Q3 | $1.18M | Hold |
33,229
| – | – | 0.15% | 236 |
|
|
2023
Q2 | $1.53M | Buy |
+33,229
| New | +$1.53M | 0.21% | 169 |
|
|
2021
Q3 | – | Sell |
-12,129
| Closed | -$1.16M | – | 883 |
|
|
2021
Q2 | $1.16M | Buy |
+12,129
| New | +$1.16M | 0.08% | 350 |
|